Next report date
Report period
Q1 2024
EPS estimate
−0.07EUR
Revenue estimate
42.71 MEUR
−0.250EUR
−47.04 MEUR
176.33 MEUR
186.87 M
About Akebia Therapeutics, Inc.
Sector
CEO
John P. Butler
Headquarters
Cambridge
Website
Employees (FY)
167
Founded
2007
FIGI
BBG0066H96C6
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange AKEBIA THERAPEUT.DL-00001 stocks are traded under the ticker AX9.
AKEBIA THERAPEUT.DL-00001 is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
AX9 earnings for the last quarter are −0.08 EUR per share, whereas the estimation was −0.08 EUR resulting in a 5.88% surprise. The estimated earnings for the next quarter are −0.03 EUR per share. See more details about AKEBIA THERAPEUT.DL-00001 earnings.
AKEBIA THERAPEUT.DL-00001 revenue for the last quarter amounts to 39.73 M EUR despite the estimated figure of 45.58 M EUR. In the next quarter revenue is expected to reach 50.19 M EUR.
Yes, you can track AKEBIA THERAPEUT.DL-00001 financials in yearly and quarterly reports right on TradingView.
AX9 net income for the last quarter is 555.38 K EUR, while the quarter before that showed −13.71 M EUR of net income which accounts for 104.05% change. Track more AKEBIA THERAPEUT.DL-00001 financial stats to get the full picture.
No, AX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AKEBIA THERAPEUT.DL-00001 stock right from TradingView charts — choose your broker and connect to your account.
As of May 2, 2024, the company has 167.00 employees. See our rating of the largest employees — is AKEBIA THERAPEUT.DL-00001 on this list?
We've gathered analysts' opinions on AKEBIA THERAPEUT.DL-00001 future price: according to them, AX9 price has a max estimate of 5.54 EUR and a min estimate of 3.69 EUR. Read a more detailed AKEBIA THERAPEUT.DL-00001 forecast: see what analysts think of AKEBIA THERAPEUT.DL-00001 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AKEBIA THERAPEUT.DL-00001 EBITDA is −7.92 M EUR, and current EBITDA margin is −2.17%. See more stats in AKEBIA THERAPEUT.DL-00001 financial statements.